JMP Securities Initiates Coverage On Elevation Oncology with Market Outperform Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Market Outperform rating and a price target of $7.
March 01, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevation Oncology receives a Market Outperform rating from JMP Securities with a price target of $7.
The initiation of coverage by JMP Securities with a Market Outperform rating and a specific price target of $7 is a positive signal for Elevation Oncology. This endorsement by a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100